GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: KX-02 | KX2 361 | KX2361
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: KX2-361 is a small molecule with a dual mode of action. It is a Src kinase inhibitor and an inhibitor of tubulin polymerization [1]. It is being investigated for antiproliferative potential. It is closely related to tirbanibulin, and like KX2-391 is a peptide substrate site binder rather than a competitive ATP binding site inhibitor. KX2-361 is orally bioavailable and shows a significant level of brain tissue exposure following oral administration.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| KX2-361 is being evaluated in Phase 1 safety, tolerability and pharmacokinetics clinical trial as an antiproliferative therapy for advanced malignancies that are refractory to conventional drugs (see NCT02326441). | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT02326441 | Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies | Phase 1 Interventional | Athenex, Inc. | ||